Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP7 | P09237 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.30 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4740510 | 1.00 | EPHX1 (0.37) | EPHX1DPP4ALDH1A1MMP1MMP2 | |
| SCHEMBL1614329 | 0.77 | EPHX1 (0.32) | EPHX1 | |
| SCHEMBL18706685 | 0.75 | EPHX1 (0.31) | EPHX1 | |
| SCHEMBL1064167 | 0.74 | — | — | |
| SCHEMBL32677608 | 0.73 | CYP3A4 (0.48) | EPHX1DPP4ALDH1A1 | |
| SCHEMBL32677609 | 0.73 | CYP3A4 (0.48) | EPHX1DPP4ALDH1A1 | |
| SCHEMBL26349710 | 0.73 | CYP3A4 (0.48) | EPHX1DPP4ALDH1A1 | |
| SCHEMBL31355393 | 0.73 | EPHX1 (0.43) | EPHX1DPP4ALDH1A1 | |
| SCHEMBL22609005 | 0.72 | SLC1A3 (0.36) | MMP1MMP2MMP3MMP13 | |
| SCHEMBL22609004 | 0.72 | SLC1A3 (0.36) | MMP1MMP2MMP3MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6531484-B2 | Viricides for preventing infection by HIV, treating infection by HIV, delaying of the onset of AIDS, or treating AIDS | MERCK & CO., INC. | 2003-03-11 | — | — | US | disclosed |
| US-20020198178-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198178-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | CCR5, CCR1, CCL5 | EPHX1 3785/4885DPP4 3549/4885ALDH1A1 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.